A Look At iRhythm Holdings (IRTC) Valuation After Recent Share Price Weakness

Why iRhythm Holdings is on investors' radar today

iRhythm Holdings (IRTC) has drawn attention after a recent stretch of weak share performance, with the stock showing negative returns over the past week, month and past 3 months.

For investors, that pullback sits alongside positive annual revenue and net income growth, as well as a small positive 3 year total return and a higher 1 year total return. This combination is inviting a closer look at how the business is currently positioned.

See our latest analysis for iRhythm Holdings.

The recent 1 day share price return of a 1.46% decline adds to a 7 day share price return of an 8.57% decline and a 30 day share price return of a 21.64% decline. However, the 1 year total shareholder return of 12.25% and flat 3 year total shareholder return suggest longer term holders have had a very different experience from those focused on the recent pullback.

If iRhythm’s digital cardiac monitoring story has your attention, this could be a good moment to see what else is available and check out 33 healthcare AI stocks as a fresh set of ideas beyond a single stock.

With the shares recently weaker, a value score of 4, an intrinsic discount of around 51% and a market price well below some analyst targets, you have to ask: is this a genuine opening or is future growth already priced in?

Most Popular Narrative: 46.9% Undervalued

Against the last close of $113, the most followed narrative sees fair value closer to $212.87, framing iRhythm as materially mispriced by the market today.

The growing push towards population health management, preventative care, and value-based reimbursement is aligning directly with Zio's evidence-supported, scalable monitoring platform, supporting both recurring usage and improved payer coverage, which should drive higher revenues and improved net margins over time.

Read the complete narrative.

Want to see what sits behind that confidence in future cash flows and margins? The narrative leans heavily on sustained revenue growth and a richer earnings profile built into its fair value path.

Result: Fair Value of $212.87 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upside case still runs into real friction if regulatory inquiries drag on or new competitors and AI tools chip away at pricing power and growth expectations.

Find out about the key risks to this iRhythm Holdings narrative.

Another View: Revenue Multiple Sends a Different Signal

That 46.9% gap to our fair value and discounted cash flow view sits alongside a very different message from the P/S ratio. iRhythm trades on 4.9x sales, compared with 2.8x for the wider US Medical Equipment group and an estimated fair ratio of 3.9x. This raises the question of whether the shares represent a bargain or reflect a richly priced growth story supported by cash flow assumptions.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals so far, right, with both weak recent returns and a stronger one year result on the table. It makes sense to move quickly and review the underlying numbers yourself, then weigh up 3 key rewards and 1 important warning sign before you decide where you stand.

Ready for more investment ideas?

If this iRhythm story has you thinking more broadly, do not stop here, use the Simply Wall Street Screener to line up your next set of candidates.

• Target potential bargains by scanning our wide set of 48 high quality undervalued stocks that pair lower prices with stronger fundamental profiles.
• Prioritise resilience with 68 resilient stocks with low risk scores, focusing on companies that score well on stability so short term swings are less likely to derail your plan.
• Seek out future winners early by checking our screener containing 26 high quality undiscovered gems, where solid fundamentals have not yet attracted broad market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com